Literature DB >> 14715557

Identification of primary and secondary measles vaccine failures by measurement of immunoglobulin G avidity in measles cases during the 1997 São Paulo epidemic.

Cláudio S Pannuti1, Ricardo José Morello, José Cássio de Moraes, Suely Pires Curti, Ana Maria S Afonso, Maria Cláudia Corrêa Camargo, Vanda A U F de Souza.   

Abstract

Despite almost universal use of measles vaccines in recent decades, epidemics of the disease continue to occur. Understanding the role of primary vaccine failure (failure to seroconvert after vaccination) and secondary vaccine failures (waning immunity after seroconversion) in measles epidemics is important for the evaluation of measles control programs in developing countries. After a measles epidemic in São Paulo, Brazil, 159 cases previously confirmed by detection of specific immunoglobulin M (IgM) antibodies were tested for IgG avidity, and a secondary immune response, defined by an IgG avidity index of at least 30%, was established in 30 of 159 (18.9%) patients. Among the 159 patients, 107 (67.3%) had not been vaccinated and 52 (32.7%) had received one or more doses of measles vaccine. Of the 107 unvaccinated patients, 104 (97.2%) showed a primary immune response, defined as an IgG avidity index of less than 30%. Among the 52 patients with documented vaccination, 25 (48.1%) showed a primary immune response and 27 (51.9%) showed a secondary immune response, thereby constituting a secondary vaccine failure. Primary vaccine failure was observed in 13 of 13 patients vaccinated prior to 1 year of age and in 43.5 and 12.5%, respectively, of patients receiving one or two doses after their first birthdays. These results provide evidence that measurement of IgG avidity can be used to distinguish between primary and secondary vaccine failures in vaccinated patients with measles; the method can also be a useful tool for the evaluation of measles control programs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14715557      PMCID: PMC321355          DOI: 10.1128/cdli.11.1.119-122.2004

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  30 in total

1.  Twice vaccinated recipients are better protected against epidemic measles than are single dose recipients of measles containing vaccine.

Authors:  M Paunio; H Peltola; M Valle; I Davidkin; M Virtanen; O P Heinonen
Journal:  J Epidemiol Community Health       Date:  1999-03       Impact factor: 3.710

2.  Improvement in establishing the period of rubella virus primary infection using a mild protein denaturant.

Authors:  F Condorelli; A Stivala; R Gallo; E Musumeci; M C Scatà; L Strano; M Pennisi; G Russo; A Castro; G Scalia
Journal:  J Virol Methods       Date:  1997-06       Impact factor: 2.014

3.  Enzyme-linked immunosorbent assay (ELISA) for measles antibody. A comparison with haemagglutination inhibition, immunofluorescence and plaque neutralization tests.

Authors:  V A de Souza; C S Pannuti; L M Sumita; P Albrecht
Journal:  Rev Inst Med Trop Sao Paulo       Date:  1991 Jan-Feb       Impact factor: 1.846

4.  Serological and clinical characteristics of measles vaccine failure in Japan.

Authors:  Y Hidaka; T Aoki; H Akeda; C Miyazaki; K Ueda
Journal:  Scand J Infect Dis       Date:  1994

5.  Secondary immune response in a vaccinated population during a large measles epidemic.

Authors:  G Ozanne; M A d'Halewyn
Journal:  J Clin Microbiol       Date:  1992-07       Impact factor: 5.948

6.  Immunoglobulin M antibody response to measles virus following primary and secondary vaccination and natural virus infection.

Authors:  D D Erdman; J L Heath; J C Watson; L E Markowitz; W J Bellini
Journal:  J Med Virol       Date:  1993-09       Impact factor: 2.327

7.  Baculovirus expression of the nucleoprotein gene of measles virus and utility of the recombinant protein in diagnostic enzyme immunoassays.

Authors:  K B Hummel; D D Erdman; J Heath; W J Bellini
Journal:  J Clin Microbiol       Date:  1992-11       Impact factor: 5.948

Review 8.  Diagnosis and management of human cytomegalovirus infection in the mother, fetus, and newborn infant.

Authors:  Maria Grazia Revello; Giuseppe Gerna
Journal:  Clin Microbiol Rev       Date:  2002-10       Impact factor: 26.132

9.  Immunoglobulin G antibody avidity assay for serodiagnosis of hepatitis C virus infection.

Authors:  Atsushi Kanno; Yukumasa Kazuyama
Journal:  J Med Virol       Date:  2002-10       Impact factor: 2.327

10.  Detection of low-avidity immunoglobulin G in oral fluid samples: new approach for rubella diagnosis and surveillance.

Authors:  D Akingbade; B J Cohen; D W G Brown
Journal:  Clin Diagn Lab Immunol       Date:  2003-01
View more
  23 in total

1.  Measles virus-specific antibody levels in individuals in Argentina who received a one-dose vaccine.

Authors:  Marcelo H Argüelles; Mariana L Orellana; Alejandro A Castello; Guillermo A Villegas; Matilde Masini; Alejandra L Belizan; Silvia González Ayala; Osmar D Vera; Graciela Glikmann
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

2.  Seroprevalence of antibodies to measles and rubella eight months after a vaccination campaign in the southeast of Iran.

Authors:  Shahrokh Izadi; Seyed Mohsen Zahraei; Talat Mokhtari-Azad
Journal:  Hum Vaccin Immunother       Date:  2018-02-26       Impact factor: 3.452

3.  Characterization of immune responses induced by intramuscular vaccination with DNA vaccines encoding measles virus hemagglutinin and/or fusion proteins.

Authors:  Man Ki Song; Christofer J Vindurampulle; Alejandra V E Capozzo; Jeffrey Ulmer; John M Polo; Marcela F Pasetti; Eileen M Barry; Myron M Levine
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

4.  Outbreak of measles among persons with secondary vaccine failure, China, 2018.

Authors:  Zhujiazi Zhang; Meng Chen; Rui Ma; Jingbin Pan; Luodan Suo; Li Lu
Journal:  Hum Vaccin Immunother       Date:  2019-09-05       Impact factor: 3.452

Review 5.  Development of next-generation respiratory virus vaccines through targeted modifications to viral immunomodulatory genes.

Authors:  Christopher C Stobart; Martin L Moore
Journal:  Expert Rev Vaccines       Date:  2015-10-05       Impact factor: 5.217

Review 6.  Measles, the need for a paradigm shift.

Authors:  Emilie Javelle; Philippe Colson; Philippe Parola; Didier Raoult
Journal:  Eur J Epidemiol       Date:  2019-10-17       Impact factor: 8.082

7.  Evaluation of potentially achievable vaccination coverage of the second dose of measles containing vaccine with simultaneous administration and risk factors for missed opportunities among children in Zhejiang province, east China.

Authors:  Yu Hu; Yaping Chen; Ying Wang; Hui Liang
Journal:  Hum Vaccin Immunother       Date:  2018-01-23       Impact factor: 3.452

8.  Measles virus IgG avidity assay for use in classification of measles vaccine failure in measles elimination settings.

Authors:  Sara Mercader; Philip Garcia; William J Bellini
Journal:  Clin Vaccine Immunol       Date:  2012-09-12

Review 9.  The genetic basis for interindividual immune response variation to measles vaccine: new understanding and new vaccine approaches.

Authors:  Iana H Haralambieva; Inna G Ovsyannikova; V Shane Pankratz; Richard B Kennedy; Robert M Jacobson; Gregory A Poland
Journal:  Expert Rev Vaccines       Date:  2013-01       Impact factor: 5.217

10.  Why does measles persist in Europe?

Authors:  P Plans-Rubió
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-05-26       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.